Publications by authors named "David M Shlaes"

Claim this Profile
I
Innovation, Nontraditional Antibacterial Drugs, and Clinical Utility.
David M Shlaes

ACS Infect Dis· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Europe Pull It Together?
David M Shlaes

Clin Infect Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibacterial Drugs: The Last Frontier.
David M Shlaes

ACS Infect Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personal View of the Antibiotic Value Proposition.
David M Shlaes

ACS Infect Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Economic Conundrum for Antibacterial Drugs.
David M Shlaes

Antimicrob Agents Chemother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it.
David M Shlaes, Patricia A Bradford

Pathog Immun· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research and Development of Antibiotics: The Next Battleground.
David M Shlaes

ACS Infect Dis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to "Simple solutions reflect misunderstanding of animal antibiotic use".
Matthew Metz, David M Shlaes

Antimicrob Agents Chemother· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eight more ways to deal with antibiotic resistance.
Matthew Metz, David M Shlaes

Antimicrob Agents Chemother· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In memoriam: John P. Quinn, MD.
Federico Perez, Cesar A Arias, Karen Bush, George L Drusano, Karen Lolans, David M Shlaes

Clin Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FDA reboot of antibiotic development.
David M Shlaes, Dan Sahm, Carol Opiela, Brad Spellberg

Antimicrob Agents Chemother· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New β-lactam-β-lactamase inhibitor combinations in clinical development.
David M Shlaes

Ann N Y Acad Sci· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming the challenges to developing new antibiotics.
David M Shlaes, Brad Spellberg

Curr Opin Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pleuromutilin antibiotics: a new class for human use.
Rodger Novak, David M Shlaes

Curr Opin Investig Drugs· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases.
Aranapakam M Venkatesan, Atul Agarwal, Takao Abe, Hideki Ushirogochi, Mihira Ado, David M Shlaes

Bioorg Med Chem· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telithromycin and the FDA: implications for the future.
David M Shlaes, Robert C Moellering

Lancet Infect Dis· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
Aranapakam M Venkatesan, Atul Agarwal, Takao Abe, Hideki Ushirogochi, Itsuka Yamamura, David M Shlaes

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria.
Youjun Yang, Anatoly Severin, Rajiv Chopra, Girija Krishnamurthy, Guy Singh, David M Shlaes

Antimicrob Agents Chemother· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An update on tetracyclines.
David M Shlaes

Curr Opin Investig Drugs· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.
Aranapakam M Venkatesan, Atul Agarwal, Takao Abe, Hideki Ushirogochi, Itsuki Yamamura, David M Shlaes

Bioorg Med Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria.
Russell G Dushin, Ting-Zhong Wang, Phaik-Eng Sum, Haiyin He, Alan G Sutherland, David M Shlaes

J Med Chem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria.
Alexey Ruzin, Guy Singh, Anatoly Severin, Youjun Yang, Russell G Dushin, David M Shlaes

Antimicrob Agents Chemother· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The abandonment of antibacterials: why and wherefore?
David M Shlaes

Curr Opin Pharmacol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.
Alexey Ruzin, Anatoly Severin, Soraya L Moghazeh, Jerome Etienne, Patricia A Bradford, David M Shlaes

Biochim Biophys Acta· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.
Alexey Ruzin, Anatoly Severin, Frank Ritacco, Keiko Tabei, Guy Singh, David M Shlaes

J Bacteriol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis